Teva Pharmaceutical Industries Aktie
WKN: 883035 / ISIN: US8816242098
|
02.09.2026 13:33:08
|
Teva Pharma Reports Positive Topline Results From Ongoing Phase 2a Study Of TEV 408
(RTTNews) - Teva Pharmaceutical Industries (TEVA) announced positive topline results from an ongoing Phase 2a study of TEV 408, an investigational anti-interleukin-15 monoclonal antibody, in adults with celiac disease. The study met primary endpoint, demonstrating statistically significant and clinically meaningful prevention of gluten-induced intestinal damage versus placebo at week 8.
Additional analyses from the ongoing Phase 2a study are underway. The company plans to present further data from the study at a future scientific meeting.
In pre-market trading on NYSE, Teva shares are up 2.96 percent to $37.27.
For More Such Health News, visit rttnews.com.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)
Analysen zu Teva Pharmaceutical Industries Ltd. (spons. ADRs)
Aktien in diesem Artikel
| Teva Pharmaceutical Industries Ltd. (spons. ADRs) | 31,20 | -0,32% |
|